With two new approvals for the vaunted checkpoint inhibitor Keytruda and a rapidly expanding oncology pipeline following M&A deals, Merck & Co. plans to share outlines for the future of the company’s cancer treatment at the first investor day held in five years.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Sanofi said a reorganization of the company’s research and development operation in Germany and France would result in 466 job cuts in the two countries.
Gilead Sciences Inc. and Nurix Therapeutics Inc. announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.
June 2019 is a busy month for approval applications for the U.S. Food and Drug Administration as the regulatory agency has a slate of PDUFA dates.
Abbott’s Afinion HbA1c Dx assay was launched as the only rapid point-of-care test cleared by the U.S. Food and Drug Administration to aid healthcare professionals in the diagnosis of diabetes and the assessment of patients’ risk of developing the condition.
Pfizer Inc. struck a deal with an enterprise value of about $11.4 billion to buy Array BioPharma Inc. to expand the company’s portfolio of potentially lucrative cancer drugs.
U.S. drugmakers filed a lawsuit challenging a new government regulation that would require them to disclose the list price of prescription drugs in direct-to-consumer television advertisements.
Vancouver-based AbCellera and Gilead Sciences forged a collaborative agreement to discover and develop ultra-rare antibodies that can be used in the treatment of a number of infectious diseases.
San Francisco-based BlackThorn Therapeutics announced closing on a $76 million Series B financing round.